A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis

Multiple Sclerosis

Volumn 11, Issue 5, 2005, Pages 585-591

  Mikol, Daniel ^a   Lopez Bresnahan, M ^b   Taraskiewicz, S ^b   Chang, P ^b   Rangnow, J ^b   Angelopoulos, Mary ^c   Arazi, Richard ^d   Arlen, Fern ^e   Ash, Paul ^f   Atalla, Lilly ^g   Au, William ^g   Ayres, Donald W ^h   Bashir, Khurram ⁱ   Bass, Ann ^g   Bernard, Jacqueline ^j   Bever, Christopher ^k   Birnbaurn, Gary ^l   Blanck, Richard ^g   Blue, Susan K ^m   Blumenfeld, Andrew ⁿ   Bodziner, Richard ^o   Borresen, Thor E ^p   Bowman, Michael ^q   Brandes, David W ^r   Brod, Staley A ^s   Brownstone, Paul ^t   Burkholder, James D ^u   Cain, Robert ^g   Cardelli, Dominic ^g   Cascione, Mark C ^v   Cleeremans, Bruce ^w   Cook, Stuart ^t   Cooper, Joanna ^g   Coyle, Patricia ^x   Cross, Anne H ^y   Curfman, Thomas J ^z   Dahlquist, Neil ^g   Detrich, Terry P ^g   Dhaduk, Vithalbhai D ^g   Dickson, Richard A ^aa   Dietrich, Dennis W ^ab   Dihenia, Bhupesh ^g   Dunne, Peter B ^ac   Echols, Charles L ^ad   Eilender, Lawrence ^g   Elias, Stanton B ^y   Epstein, Michael A ^g   Estronza, Nordeli ^ae   Eubank, Geoffrey A ^af   Fox, Edward ^g   Fox, Stuart ^ag   Frere, Robert C ^ah   Gambin, John ^ai   Garrison, James E ^aj   Gaskin, Annmarie ^ak   Gazda, Suzanne K ^al   Gilroy, John ^g   Ginsburg, David ^am   Goetzl, Ugo ^an   Gosy, Eugene ^ao   Green, Phillip M ^ap   Greene, Wayne ^g   Gross, Jeffrey L ^aq   Guarnaccia, Joseph B ^ar,as   Gudesblatt, Mark ^at   Gwynn, Mathews W ^au   Hayat, Ghazala ^av   Hollenbeck, Larry ^aw   Honeycutt, W David ^g   Hsu, Philip S ^ax   Hughes, Bruce ^ay   Hurwitz, Barrie J ^az   Husar, Walter G ^ba   Jacobs, Daniel H ^bb   Jacobs, Alan K ^bc   Janjua, Riaz A ^g   Jeffrey, Douglas R ^ap   Kaner, Jay ^g   Kasper, Lloyd ^bd   Kaufman, Michael D ^a   Kelman, Leslie ^ar   Khatri, Bhupendra O ^as   Kinkel, Peter ^at   Kirzinger, Stephen ^au   Kita, Mariko ^av   Knobler, Robert L ^aw   Kolar, Oldrich J ^be   Kott, H Stephen ^ax   Landen, Ivan R ^ay   Leist, Thomas ^bf   Lellelid, Nancy ^ba   Levin, Jeffrey R ^g   Levin, Kenneth ^bg   Likosky, William ^bc   Loganbill, Heidi ^g   Lublin, Fred D ^bh   Lucas, Sylvia ^bi   Maher, Leo ^bj   Mandler, Raul N ^bk   more..

^a UNIVERSITY OF MICHIGAN   (United States)

^b EMD SERONO INC   (United States)

^c Cook Neurological Consultants ^*  (United States)

^d Dakota Neurology   (United States)

^e Four Peaks Neurology   (United States)

^f Oregon Neurology PC   (United States)

^g Upper Valley Neurology Neurosurgery ^*

^h Minneapolis Clinic of Neurology   (United States)

ⁱ The University of Alabama at Birmingham   (United States)

^j Neurological Services of Texas   (United States)

^k KAISER PERMANENTE   (United States)

^l Neurological Institute of Savannah   (United States)

^m Raleigh Neurology Associates   (United States)

ⁿ Northridge MS Center   (United States)

^o UNIVERSITY OF TEXAS   (United States)

^p Alpine Clinical Research Center   (United States)

^q Rush University   (United States)

^r Axiom Clinical Research of Florida   (United States)

^s NervePro Research   (United States)

^t RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^u East Bay Neurology   (United States)

^v Fort Wayne Neurological Center   (United States)

^w Clinical Research Department   (United States)

^x BARROW NEUROLOGICAL INSTITUTE   (United States)

^y HENRY FORD HOSPITAL   (United States)

^z Crisis Services   (United States)

^aa Humboldt Neurological Medical Group Inc   (United States)

^ab Bexar Diagnostic Medical Associates PA   (United States)

^ac Texas Neurosciences Institute   (United States)

^ad Nevada Power Co   (United States)

^ae Southern Connecticut PC   (United States)

^af GRIFFIN HOSPITAL   (United States)

^ag South Shore Neurologic Associates   (United States)

^ah EAST CAROLINA UNIVERSITY   (United States)

^ai SAINT LOUIS UNIVERSITY   (United States)

^aj Northland Neurological   (United States)

^ak Neurosurg and Neurol Group Inc   (United States)

^al Mercy Ruan Neurology Clinic   (United States)

^am Central Morris Neurology   (United States)

^an Neurology Service of Orlando   (United States)

^ao The Neurology Center   (United States)

^ap WAKE FOREST SCHOOL OF MEDICINE   (United States)

^aq CAROLINAS MEDICAL CENTER   (United States)

^ar Headache Center of Atlanta   (United States)

^as Wheaton Franciscan Healthcare St Francis   (United States)

^at DENT NEUROLOGIC INSTITUTE   (United States)

^au Louisville Neuroscience Research Ctr   (United States)

^av VIRGINIA MASON MEDICAL CENTER   (United States)

^aw The KIND Clinic   (United States)

^ax LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^ay Hackley Professional Center   (United States)

^az THOMAS JEFFERSON UNIVERSITY   (United States)

^ba The Everett Clinic   (United States)

^bb Neurology Group of Bergen County   (United States)

^bc Minor and James Medical   (United States)

^bd DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^be Indiana Ctr for Multiple Sclerosis   (United States)

^bf THOMAS JEFFERSON UNIVERSITY   (United States)

^bg Neurology Group of Bergen County   (United States)

^bh MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^bi Swedish Headache Center   (United States)

^bj Staff Development Supervisor   (United States)

^bk GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Autoinjector; Compliance; Injection site reactions; Side effets

Indexed keywords

BETA1A INTERFERON; LIVER ENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FEVER; ENZYME DEFECT; FEMALE; FLU LIKE SYNDROME; HUMAN; INCIDENCE; INJECTION; INJECTION PAIN; INJECTION SITE REACTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MYALGIA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; STATISTICAL ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROLOGIC EXAMINATION; PATIENT COMPLIANCE; SELF ADMINISTRATION; TREATMENT OUTCOME;

EID: 25844457405     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1197oa     Document Type: Article

References (14)

1. Paty DW, Hartung HP, Ebers GC, Soelberg-Sorensen P, Abramsky O, Kesselring J et al. Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines. Eur J Neurol 1999; 6: S1-35.
2. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992; 31: 333-36.
3. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
4. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001; 56: 1628-36.
5. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
6. Rudick R, Goodkin D, Jacobs L, Cookfair DL, Herndon RM, Richert JR et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997; 49: 358-63.
7. Patti F, Reggio A. Interferon β and multiple sclerosis: look at the evidence. Int J Clin Pract 2002; Suppl 131: 23-32.
8. Panitch HS, Goodin S, Francis G, Chang P, Coyle PK, O'Connor P et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002; 59: 1496-506.
9. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
10. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
11. Walther E, Hohlfeld R. Multiple sclerosis. Side-effects of interferon beta therapy and their management. Neurology 1999; 53: 1622-27.
12. Secondary Progressive Efficacy Trial of Recombinant Interferon beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon beta-1a in secondary progressive MS. Neurology 2001; 56: 1496-504.
13. Lesaux J, Jadbäck G, Harragby CE. Improving the convenience of home-based interferon beta-1a therapy for multiple sclerosis. J Neurosci Nurs 1999; 21: 174-79.
14. Bosely EB, Capildeo R. Early use of interferon β in patients with multiple sclerosis. Int J Clin Pract 2002; Suppl 131: 17-22.